AstraZeneca Pharma will exit manufacturing at its only plant based in Bangalore, as part of a ``global strategic review’’. The company with revenues of over Rs 1000 crore, feels that it can derive more value for its shareholders by transferring core manufacturing to a contract manufacturer. As a part of AstraZeneca's ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore, in due course, it said in a stock exchange filing.
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/UnuTL8Q
Subscribe to:
Post Comments (Atom)
SIP flows scale Rs 20,000 crore mark 1st time
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/IStK8Pv
-
A woman, in her early 20s, was stabbed to death by a man in southeast Delhi's Bhogal area on Friday evening, following which the accused...
-
The Delhi High Court on Thursday dismissed the pleas of TTV Dhinakaran and VK Sasikala challenging the Election Commission's order grant...
-
Trading in stock markets this week will be majorly influenced by the upcoming quarterly earnings from IT majors TCS and Infosys, along with...
No comments:
Post a Comment